Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2724163 | 1.00 | CA2 (0.46) | CA2ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL3490631 | 1.00 | CA2 (0.46) | CA2ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL2859063 | 0.94 | CA2 (0.41) | CA2ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL23827433 | 0.92 | CA2 (0.44) | CA2ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL9281309 | 0.92 | CA2 (0.44) | CA2ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL7165666 | 0.91 | CA2 (0.43) | CA2ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL31688970 | 0.91 | CA2 (0.43) | CA2ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL31688849 | 0.91 | CA2 (0.43) | CA2ALDH1A1NPSR1CA12CA1 | |
| SCHEMBL898388 | 0.86 | CA2 (0.58) | CA2ALDH1A1NPSR1CYP3A4KDM4E | |
| SCHEMBL411517 | 0.86 | CA2 (0.58) | CA2ALDH1A1NPSR1CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125614-A1 | IONIZABLE CATIONIC LIPIDS | AKAGERA MEDICINES, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12606773-B2 | Ionizable cationic lipids | AKAGERA MEDICINES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260055335-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS | AKAGERA MEDICINES, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-12331264-B2 | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof | AKAGERA MEDICINES, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2024074814-A9 | COMPOSITION COMPRISING A FUNCTIONALISED DYE AND A DIALLYLAMINE COMONOMER AND USE THEREOF | SUBLINO LIMITED (GB) | 2025-05-22 | — | — | WO | disclosed |
| US-20240309291-A1 | IONIZABLE CATIONIC LIPIDS | AKAGERA MEDICINES, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-12077725-B2 | Ionizable cationic lipids | AKAGERA MEDICINES, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4251170-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE | Akagera Medicines, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230126953-A1 | IONIZABLE CATIONIC LIPIDS | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN-LA ROCHE, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2009047161-A1 | CHIRAL CIS-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008094054-A2 | 6, 8-DICHLORCHROMAN-3-YL-L, 3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | BIAL-PORTELA & CA, S.A. (PT) | 2008-08-07 | — | — | WO | disclosed |
| EP-0530343-B1 | WATER SOLUBLE, NON-IONIC X-RAY CONTRASTING AGENTS AND PROCESS FOR PRODUCING THE SAME | KOEHLER CHEMIE DR FRANZ (DE) | 1995-09-20 | — | — | EP | disclosed |
| WO-1993024490-A1 | USE OF INDOLOCARBAZOLS IN AIDS TREATMENT | Gödecke Aktiengesellschaft (DE) | 1993-12-09 | — | — | WO | disclosed |
| US-4672071-A | Antihypertensive dihydropyridine compositions, optical isomers and intermediates | SYNTEX (U.S.A.) INC. (US) | 1987-06-09 | — | — | US | disclosed |
| EP-0191448-A2 | Antihypertensive dihydropyridine derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| US-4595690-A | Hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1986-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | CA2 3269/4885ALDH1A1 3567/4885NPSR1 4114/4885 |
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | FOXM1, CCNE1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA2 1290/4885ALDH1A1 2824/4885NPSR1 2433/4885 |
| US-12077725-B2 | Ionizable cationic lipids | PHOSPHO1, LIPA, ABHD16A | CA2 2111/4885ALDH1A1 4099/4885NPSR1 3562/4885 |
| US-20260125614-A1 | IONIZABLE CATIONIC LIPIDS | CPT2, NPC1L1, PNPLA2 | CA2 1967/4885ALDH1A1 3307/4885NPSR1 3930/4885 |
| US-12606773-B2 | Ionizable cationic lipids | NPC1L1, MCOLN1, SLC22A4 | CA2 1001/4885ALDH1A1 2574/4885NPSR1 3915/4885 |
| US-20260055335-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS | CD4, LDLR, CD2BP2 | CA2 4227/4885ALDH1A1 2719/4885NPSR1 2381/4885 |
| US-20230126953-A1 | IONIZABLE CATIONIC LIPIDS | PHOSPHO1, LIPA, ABHD16A | CA2 2111/4885ALDH1A1 4099/4885NPSR1 3562/4885 |
| US-20240309291-A1 | IONIZABLE CATIONIC LIPIDS | PHOSPHO1, LIPA, ABHD16A | CA2 2111/4885ALDH1A1 4099/4885NPSR1 3562/4885 |
| US-12331264-B2 | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof | ASGR1, LDLR, CD2BP2 | CA2 2505/4885ALDH1A1 2425/4885NPSR1 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.